Selected articles
Articles for label Arenberger Petr are displayed.. Show all articles
Locally advanced or metastatic basal cell carcinoma
02/2019 Prof. MUDr. Petr Arenberger, DrSc, MBA, FCMA
Basal cell carcinoma is the most common skin tumor, yet little attention has been paid to its treatment. The vast majority of patients are cured by surgical removal of the tumor. Other therapeutic options include radiotherapy, cryotherapy or photodynamic therapy. However, in a limited number of cases, current treatment options do not lead to cure and basal cell carcinoma develops into an advanced stage. A locally advanced stage can cause significant destruction and disfigurement of surrounding tissues. In extremely rare cases, the disease may develop into a metastatic stage that directly threatens the patient's life.
ENTIRE ARTICLE
Basal cell carcinoma is the most common skin tumor, yet little attention has been paid to its treatment. The vast majority of patients are cured by surgical removal of the tumor. Other therapeutic options include radiotherapy, cryotherapy or photodynamic therapy. However, in a limited number of cases, current treatment options do not lead to cure and basal cell carcinoma develops into an advanced stage. A locally advanced stage can cause significant destruction and disfigurement of surrounding tissues. In extremely rare cases, the disease may develop into a metastatic stage that directly threatens the patient's life.
BRAF/MEK inhibitors in the treatment of malignant melanoma
03/2018 Prof. MUDr. Petr Arenberger, DrSc., MBA, FCMA
Metastatic melanoma was still relatively recently considered as a malignant tumor with a very poor prognosis, with only limited response to the available treatment methods. However, over the last five years, at least in part of the patients, metastatic melanoma has been slowly changing from being a disease with poor prognosis to disease with long-term survival. It is mostly due to new therapeutic options. Ten years ago, five-year survival rate was no more than 10% of patients. Nowadays, using the latest therapeutic options, the number is approximately 30%.
ENTIRE ARTICLE
Metastatic melanoma was still relatively recently considered as a malignant tumor with a very poor prognosis, with only limited response to the available treatment methods. However, over the last five years, at least in part of the patients, metastatic melanoma has been slowly changing from being a disease with poor prognosis to disease with long-term survival. It is mostly due to new therapeutic options. Ten years ago, five-year survival rate was no more than 10% of patients. Nowadays, using the latest therapeutic options, the number is approximately 30%.